Did You Lose Money on Regeneron Pharmaceuticals, Inc. (REGN)?
A securities class action has been filed on behalf of investors who purchased or acquired Regeneron Pharmaceuticals, Inc. securities during the class period below and suffered a financial loss.
- Ticker / Exchange
- REGN · NASDAQ
- Class Period
- November 2, 2023 – May 30, 2025
- Reported Decline
- -11.4%
Lead Plaintiff Deadline
September 29, 2026
45 days remaining
- No cost or obligation to participate
- Attorneys work on a contingency-fee basis
- Confidential case review by experienced counsel
Company
Regeneron Pharmaceuticals, Inc.
Class Period
November 2, 2023 – May 30, 2025
Lead Plaintiff Deadline
September 29, 2026
Case Type
Securities Class Action
Reported Stock Decline
-11.4%
What Is the REGN Lawsuit About?
A securities class action has been filed alleging that Regeneron Pharmaceuticals, Inc. and certain of its officers made materially false and misleading statements regarding the commercial trajectory of a key product and the impact of competitive and reimbursement dynamics. According to the complaint, defendants allegedly minimized known headwinds while issuing positive guidance. When the alleged true state of affairs was revealed, the price of Regeneron securities fell, causing losses to affected investors during the class period.
These are allegations contained in the filed complaint. No court has made a final determination regarding the merits of the claims.
Key Allegations
- Defendants allegedly minimized known competitive headwinds.
- Reimbursement dynamics are alleged to have been understated.
- Guidance is alleged to have lacked a reasonable basis.
- Investors allegedly suffered losses upon corrective disclosures.
Reported Market Reaction
- Disclosure / Event Date
- May 30, 2025
- Percentage Decline
- -11.4%
- Closing Price
- $742.00
Stock-price information is provided for context and does not establish liability or guarantee any recovery.
Who May Be Eligible?
You may be eligible if you purchased or acquired Regeneron Pharmaceuticals, Inc. securities during the class period and suffered a financial loss. The class period runs from November 2, 2023 to May 30, 2025.
- You purchased or acquired Regeneron Pharmaceuticals, Inc. securities during the class period.
- You suffered a financial loss in connection with those holdings.
- You do not necessarily need to serve as lead plaintiff to potentially participate in any future recovery. The lead plaintiff is a representative party who acts on behalf of other class members; class members may participate without taking on that role.
The lead plaintiff deadline is September 29, 2026.
Check My EligibilityWhat Happens Next
- 1
Submit Your Information
Complete the short form so the team can identify the case and your potential eligibility.
- 2
Eligibility and Transaction Review
Additional transaction records or brokerage statements may be requested to evaluate your submission.
- 3
The Legal Team May Contact You
If appropriate, a member of the team may reach out to discuss next steps regarding this matter.
Why Investors Contact Levi & Korsinsky
Securities Litigation Experience
Approved firm credential — supply approved copy describing the firm's securities litigation practice.
Verified Settlement History
Verified settlement figure — insert legally approved recovery figures from the CMS.
Secure and Confidential Review
Your submission is handled confidentially and used to evaluate this matter.
No Upfront Cost
Approved no-upfront-cost statement — display only if approved by the legal team.
Attorney advertising. Prior results do not guarantee a similar outcome. Statements marked as requiring approval are placeholders pending legal review.
Questions & answers
Frequently asked questions
Other Active Investigations
Investors in these companies may also be eligible to participate.